AAN unveils new guidelines for MS disease-modifying therapy

Following on from a recent European Academy of Neurology guideline on pharmacological treatment of multiple sclerosis (MS), the American Academy of Neurology has issued an updated practice guideline on disease-modifying therapies (DMTs) for MS. The guideline provides 30 general recommendations for initiating, switching and stopping DMTs, and indicates future research directions.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Baecher-Allan, C., Kaskow, B. J. & Weiner, H. L. Multiple sclerosis: mechanisms and immunotherapy. Neuron 97, 742–768 (2018).

    Article  PubMed  CAS  Google Scholar 

  2. 2.

    Larochelle, C., Uphaus, T., Prat, A. & Zipp, F. Secondary progression in multiple sclerosis: neuronal exhaustion or distinct pathology? Trends Neurosci. 39, 325–339 (2016).

    Article  PubMed  CAS  Google Scholar 

  3. 3.

    Rae-Grant, A. et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology 90, 777–788 (2018).

    Article  PubMed  Google Scholar 

  4. 4.

    Montalban, X. et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Eur. J. Neurol. 25, 215–237 (2018).

    Article  PubMed  CAS  Google Scholar 

  5. 5.

    D’Amico, E., Zanghi, A., Leone, C., Tumani, H. & Patti, F. Treatment-related progressive multifocal leukoencephalopathy in multiple sclerosis: a comprehensive review of current evidence and future needs. Drug Saf. 39, 1163–1174 (2016).

    Article  PubMed  CAS  Google Scholar 

  6. 6.

    Berger, J. R. et al. Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology 90, e1815–e1821 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  7. 7.

    Gieselbach, R. J. et al. Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases. J. Neurol. 264, 1155–1164 (2017).

    Article  PubMed  CAS  Google Scholar 

  8. 8.

    Kalincik, T. et al. Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. Brain 140, 2426–2443 (2017).

    Article  PubMed  Google Scholar 

  9. 9.

    Disanto, G. et al. Serum Neurofilament light: a biomarker of neuronal damage in multiple sclerosis. Ann. Neurol. 81, 857–870 (2017).

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. 10.

    Siller, N. et al. Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis. Mult. Scler. (2018).

    Article  Google Scholar 

Download references


The authors thank C. Ernest for proofreading the manuscript. The authors’ work is funded by the German Research Foundation (DFG) and the German Federal Ministry of Education and Research (BMBF).

Author information



Corresponding author

Correspondence to Frauke Zipp.

Ethics declarations

Competing interests

S.B. has recently received consultation funds from Merck Serono, Novartis, Sanofi-Aventis and Roche. F.Z. has recently received research grants from Genzyme and Merck Serono, as well as consultation funds from Roche, Merck Serono, Novartis, Sanofi-Aventis, Celgene and Octapharma.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Bittner, S., Zipp, F. AAN unveils new guidelines for MS disease-modifying therapy. Nat Rev Neurol 14, 384–386 (2018).

Download citation

Further reading


Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing